|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
|
GB1583753A
(en)
|
1976-07-14 |
1981-02-04 |
Science Union & Cie |
Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
|
TW219935B
(enExample)
|
1991-12-25 |
1994-02-01 |
Mitsubishi Chemicals Co Ltd |
|
|
WO1994026723A2
(en)
|
1993-05-14 |
1994-11-24 |
Genentech, Inc. |
ras FARNESYL TRANSFERASE INHIBITORS
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
|
SK158099A3
(en)
|
1997-05-28 |
2000-06-12 |
Rhone Poulenc Rorer Pharma |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
|
AU3033500A
(en)
|
1999-01-15 |
2000-08-01 |
Agouron Pharmaceuticals, Inc. |
Non-peptide glp-1 agonists
|
|
RU2260007C2
(ru)
|
1999-03-17 |
2005-09-10 |
Астразенека Аб |
Производные амида, способ их получения (варианты), фармацевтическая композиция, способ ингибирования
|
|
MXPA02001108A
(es)
|
1999-09-15 |
2002-08-20 |
Warner Lambert Co |
Pieridinonas como inhibidores de la cinasa.
|
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
US20030114448A1
(en)
|
2001-05-31 |
2003-06-19 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
|
CA2469813C
(en)
|
2001-12-18 |
2009-02-24 |
Merck & Co., Inc. |
Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
|
|
US7402585B2
(en)
|
2001-12-24 |
2008-07-22 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
|
AU2002249275A1
(en)
|
2002-03-08 |
2003-09-22 |
Warner-Lambert Company Llc |
Oxo azabicyclic compounds
|
|
EP1496896A4
(en)
|
2002-04-08 |
2007-10-31 |
Merck & Co Inc |
AKT INHIBITORS EFFECT
|
|
US7265378B2
(en)
|
2002-07-10 |
2007-09-04 |
E. I. Du Pont De Nemours And Company |
Electronic devices made with electron transport and/or anti-quenching layers
|
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
JP4560483B2
(ja)
|
2002-10-03 |
2010-10-13 |
ターゲジェン インコーポレーティッド |
血管静態化物質およびそれらの使用法
|
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
DE602004021558D1
(de)
|
2003-01-17 |
2009-07-30 |
Warner Lambert Co |
2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
|
|
EP1620413A2
(en)
|
2003-04-30 |
2006-02-01 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
JP4847868B2
(ja)
|
2003-05-14 |
2011-12-28 |
ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド |
化合物、及び、アミロイドベータの調節におけるその使用
|
|
RU2330851C9
(ru)
|
2003-05-23 |
2008-10-20 |
Центарис Гмбх |
ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
|
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
|
WO2005009437A1
(en)
|
2003-07-21 |
2005-02-03 |
Bethesda Pharmaceuticals, Inc. |
Design and synthesis of optimized ligands for ppar
|
|
EP1651631A1
(en)
|
2003-08-01 |
2006-05-03 |
Genelabs Technologies, Inc. |
Bicyclic imidazol derivatives against flaviviridae
|
|
CA2537224A1
(en)
|
2003-10-17 |
2005-05-06 |
4 Aza Bioscience Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
|
AU2004288709B2
(en)
|
2003-11-07 |
2011-01-06 |
Novartis Vaccines And Diagnostics, Inc. |
Methods for synthesizing quinolinone compounds
|
|
WO2005054201A1
(en)
|
2003-11-20 |
2005-06-16 |
Janssen Pharmaceutica N.V. |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
|
CA2545992A1
(en)
|
2003-11-24 |
2005-06-16 |
F. Hoffmann-La Roche Ag |
Pyrazolyl and imidazolyl pyrimidines
|
|
PL1706385T3
(pl)
|
2003-12-23 |
2011-03-31 |
Astex Therapeutics Ltd |
Pochodne pirazolu jako modulatory kinazy białkowej
|
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
|
NZ553087A
(en)
|
2004-08-31 |
2010-12-24 |
Astrazeneca Ab |
Quinazolinone derivatives and their use as B-raf inhibitors
|
|
RU2405781C2
(ru)
|
2004-10-14 |
2010-12-10 |
Ф.Хоффманн-Ля Рош Аг |
1, 5-нафтиридиназолидиноны, обладающие cdk1 антипролиферативной активностью
|
|
BRPI0518126A
(pt)
|
2004-10-15 |
2008-10-28 |
Astrazeneca Ab |
composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
|
|
CN102049048B
(zh)
|
2004-12-24 |
2013-12-25 |
西芬克斯医药有限公司 |
治疗或预防的方法
|
|
CA2597447C
(en)
|
2005-02-14 |
2014-03-25 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
|
WO2006092430A1
(de)
|
2005-03-03 |
2006-09-08 |
Universität des Saarlandes |
Selektive hemmstoffe humaner corticoidsynthasen
|
|
AU2006247833A1
(en)
|
2005-05-12 |
2006-11-23 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2006124944A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
EP1917252B1
(en)
|
2005-08-26 |
2014-01-01 |
Merck Serono SA |
Pyrazine derivatives and use as pi3k inhibitors
|
|
CA2628039A1
(en)
|
2005-11-11 |
2007-05-18 |
Aeterna Zentaris Gmbh |
Novel pyridopyrazines and their use as modulators of kinases
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
BRPI0620292B1
(pt)
|
2005-12-21 |
2021-08-24 |
Janssen Pharmaceutica N. V. |
Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
|
|
WO2007125405A2
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
|
JP2009537590A
(ja)
|
2006-05-24 |
2009-10-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四員複素環で置換された置換プテリジン
|
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
|
US20100016293A1
(en)
|
2006-07-03 |
2010-01-21 |
Rogier Adriaan Smits |
Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
|
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
１，５−ナフチリジン化合物及び有機発光素子
|
|
US20110262525A1
(en)
|
2006-12-13 |
2011-10-27 |
Schering Corporation |
Methods of treatment
|
|
CA2673736A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
EP2114941B1
(en)
|
2006-12-22 |
2015-03-25 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as fgfr inhibitors
|
|
JP2010514693A
(ja)
|
2006-12-22 |
2010-05-06 |
ノバルティス アーゲー |
Ｐｄｋ１阻害のためのキナゾリン
|
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
|
US20100234386A1
(en)
|
2007-05-10 |
2010-09-16 |
Chaudhari Amita |
Quinoxaline derivatives as pi3 kinase inhibitors
|
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
|
US20100179143A1
(en)
|
2007-05-29 |
2010-07-15 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
|
CN101784520B
(zh)
|
2007-06-20 |
2014-07-02 |
田边三菱制药株式会社 |
磺酰基丙二酰胺衍生物和其药物用途
|
|
JP5548123B2
(ja)
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法
|
|
JP2010532758A
(ja)
|
2007-07-06 |
2010-10-14 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
組み合わせ抗癌療法
|
|
EP2188292B1
(en)
|
2007-08-08 |
2013-05-29 |
GlaxoSmithKline Intellectual Property Development Limited |
2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
|
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
|
JP2010535804A
(ja)
|
2007-08-09 |
2010-11-25 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
JP5480813B2
(ja)
|
2007-11-16 |
2014-04-23 |
インサイト・コーポレイション |
Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
|
|
CA2722992A1
(en)
|
2008-05-05 |
2009-11-12 |
Schering Corporation |
Sequential administration of chemotherapeutic agents for treatment of cancer
|
|
GEP20125502B
(en)
|
2008-05-23 |
2012-04-25 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
|
WO2010059771A1
(en)
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
|
WO2010084152A1
(en)
|
2009-01-21 |
2010-07-29 |
Basilea Pharmaceutica Ag |
Novel bicyclic antibiotics
|
|
US20110288090A1
(en)
|
2009-02-02 |
2011-11-24 |
Armstrong Donna J |
Inhibitors of AKT Activity
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
JP5905385B2
(ja)
|
2009-06-12 |
2016-04-20 |
アビバックス |
早期老化、特には早老症を治療する為に有用な化合物
|
|
MX2012002274A
(es)
|
2009-09-03 |
2012-09-07 |
Bioenergenix |
Compuestos heterociclicos para la inhibicion de pask.
|
|
CA2772790C
(en)
|
2009-09-04 |
2017-06-27 |
Benjamin Bader |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
US9095596B2
(en)
|
2009-10-15 |
2015-08-04 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
|
KR20130053404A
(ko)
|
2010-03-30 |
2013-05-23 |
베르선 코포레이션 |
트롬빈 억제제로서의 다중치환된 방향족 화합물
|
|
GB201007286D0
(en)
*
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2011146591A1
(en)
|
2010-05-19 |
2011-11-24 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
|
WO2011149937A1
(en)
|
2010-05-24 |
2011-12-01 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
GB201020179D0
(en)
*
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CN102532141A
(zh)
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
|
|
WO2012104776A1
(en)
|
2011-01-31 |
2012-08-09 |
Novartis Ag |
Novel heterocyclic derivatives
|
|
CA2825894C
(en)
|
2011-02-02 |
2021-11-30 |
Amgen Inc. |
Prognosis of cancer using a circulating biomarker
|
|
JP6130305B2
(ja)
|
2011-02-23 |
2017-05-17 |
インテリカイン， エルエルシー |
キナーゼ阻害剤の組み合わせおよびそれらの使用
|
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
SI2707361T1
(sl)
|
2011-05-10 |
2017-12-29 |
Gilead Sciences, Inc. |
Zlite heterociklične spojine kot modulatorji natrijevega kanala
|
|
AU2012300317B2
(en)
|
2011-08-26 |
2016-12-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US9518029B2
(en)
|
2011-09-14 |
2016-12-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
CA2850763A1
(en)
|
2011-10-04 |
2013-04-11 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
ES2702305T3
(es)
|
2012-03-08 |
2019-02-28 |
Astellas Pharma Inc |
Nuevo producto de fusión de FGFR3
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
HK1226058A1
(zh)
|
2013-08-02 |
2017-09-22 |
亚尼塔公司 |
单独地或与其它试剂联合地使用axl/cmet抑制剂治疗多种癌症的方法
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
EP3122359B1
(en)
|
2014-03-26 |
2020-12-16 |
Astex Therapeutics Ltd. |
Combinations of an fgfr inhibitor and an igf1r inhibitor
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
PT3122358T
(pt)
|
2014-03-26 |
2021-03-04 |
Astex Therapeutics Ltd |
Combinações de inibidores do fgfr e cmet para o tratamento do cancro
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
|
WO2016134234A1
(en)
|
2015-02-19 |
2016-08-25 |
Bioclin Therapeutics, Inc. |
Methods, compositions, and kits for treatment of cancer
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|